Using a minimum valuable product and process approach would make it is possible to discipline and structure the development of biopharmaceuticals in the fastest way possible.
Wael Chahim
Advertisement
Wael Chahim is associate director, Development Unit Head at GSK, Rixensart, Belgium.
Articles by Wael Chahim
Advertisement
Latest Updated Articles
Advertisement
Advertisement
